Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.

Cerhan JR, Natkunam Y, Morton LM, Maurer MJ, Asmann Y, Habermann TM, Vasef MA, Cozen W, Lynch CF, Allmer C, Slager SL, Lossos IS, Chanock SJ, Rothman N, Hartge P, Dogan A, Wang SS.

Leuk Lymphoma. 2012 Jun;53(6):1105-12. doi: 10.3109/10428194.2011.638717. Epub 2012 Jan 3.

2.

High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas.

Shams TM.

J Egypt Natl Canc Inst. 2011 Dec;23(4):147-53. doi: 10.1016/j.jnci.2011.10.006. Epub 2011 Dec 9.

3.

Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.

Culpin RE, Sieniawski M, Angus B, Menon GK, Proctor SJ, Milne P, McCabe K, Mainou-Fowler T.

Histopathology. 2013 Dec;63(6):788-801. doi: 10.1111/his.12223. Epub 2013 Oct 1.

PMID:
24117687
4.

Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma.

Cubedo E, Gentles AJ, Huang C, Natkunam Y, Bhatt S, Lu X, Jiang X, Romero-Camarero I, Freud A, Zhao S, Bacchi CE, Martínez-Climent JA, Sánchez-García I, Melnick A, Lossos IS.

Blood. 2012 Jun 7;119(23):5478-91. doi: 10.1182/blood-2012-01-403154. Epub 2012 Apr 19.

5.

Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.

Alizadeh AA, Gentles AJ, Alencar AJ, Liu CL, Kohrt HE, Houot R, Goldstein MJ, Zhao S, Natkunam Y, Advani RH, Gascoyne RD, Briones J, Tibshirani RJ, Myklebust JH, Plevritis SK, Lossos IS, Levy R.

Blood. 2011 Aug 4;118(5):1350-8. doi: 10.1182/blood-2011-03-345272. Epub 2011 Jun 13.

6.

Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody.

Agostinelli C, Paterson JC, Gupta R, Righi S, Sandri F, Piccaluga PP, Bacci F, Sabattini E, Pileri SA, Marafioti T.

Histopathology. 2012 Jul;61(1):33-46. doi: 10.1111/j.1365-2559.2012.04198.x. Epub 2012 Mar 6.

PMID:
22394247
7.

LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.

Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS.

J Clin Oncol. 2008 Jan 20;26(3):447-54. Epub 2007 Dec 17.

8.

LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.

Lossos C, Bayraktar S, Weinzierl E, Younes SF, Hosein PJ, Tibshirani RJ, Sutton Posthumus J, DeAngelis LM, Raizer J, Schiff D, Abrey L, Natkunam Y, Lossos IS.

Br J Haematol. 2014 Jun;165(5):640-8. doi: 10.1111/bjh.12801. Epub 2014 Feb 26. Review.

9.

Usefulness of HGAL and LMO2 immunohistochemistry in the identification of follicular lymphomas of the non-gastric gastrointestinal tract.

Chapman-Fredricks J, Younes SF, Fan YS, Sandoval-Sus JD, Natkunam Y, Lossos IS.

Appl Immunohistochem Mol Morphol. 2013 May;21(3):200-4. doi: 10.1097/PAI.0b013e31826399aa.

PMID:
22914613
10.

A few good genes: simple, biologically motivated signatures for cancer prognosis.

Gentles AJ, Alizadeh AA.

Cell Cycle. 2011 Nov 1;10(21):3615-6. doi: 10.4161/cc.10.21.17835. Epub 2011 Nov 1. No abstract available.

11.

Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.

Charbonneau B, Maurer MJ, Fredericksen ZS, Zent CS, Link BK, Novak AJ, Ansell SM, Weiner GJ, Wang AH, Witzig TE, Dogan A, Slager SL, Habermann TM, Cerhan JR.

Am J Hematol. 2012 Sep;87(9):880-5. doi: 10.1002/ajh.23273. Epub 2012 Jun 20.

12.

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.

Jais JP, Haioun C, Molina TJ, Rickman DS, de Reynies A, Berger F, Gisselbrecht C, Brière J, Reyes F, Gaulard P, Feugier P, Labouyrie E, Tilly H, Bastard C, Coiffier B, Salles G, Leroy K; Groupe d'Etude des Lymphomes de l'Adulte.

Leukemia. 2008 Oct;22(10):1917-24. doi: 10.1038/leu.2008.188. Epub 2008 Jul 10.

13.

Diagnostic Utility of the Germinal Center-associated Markers GCET1, HGAL, and LMO2 in Hematolymphoid Neoplasms.

Menter T, Gasser A, Juskevicius D, Dirnhofer S, Tzankov A.

Appl Immunohistochem Mol Morphol. 2015 Aug;23(7):491-8. doi: 10.1097/PAI.0000000000000107.

PMID:
25203428
14.

Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma.

Chao C, Silverberg MJ, Martínez-Maza O, Chi M, Abrams DI, Haque R, Zha HD, McGuire M, Xu L, Said J.

Clin Cancer Res. 2012 Sep 1;18(17):4702-12. Epub 2012 Jun 18.

15.

Prognostic impact of LIM domain only 2 (LMO2) in chronic myelogenous leukaemia.

Atay MH, Ozatli D, Kelkitli E, Yildiz L, Turgut M, Guler N, Toptas T.

Histopathology. 2013 Aug;63(2):293-4. doi: 10.1111/his.12125. Epub 2013 May 23. No abstract available.

PMID:
23879574
16.

LMO2 (LIM domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with normal karyotype.

Patel JL, Pournazari P, Haggstrom SJ, Kosari F, Shabani-Rad MT, Natkunam Y, Mansoor A.

Histopathology. 2014 Jan;64(2):226-33. doi: 10.1111/his.12242. Epub 2013 Nov 6.

PMID:
24330148
17.

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD.

J Clin Oncol. 2012 Oct 1;30(28):3452-9. Epub 2012 Jul 30.

18.

BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.

Ding J, Dirks WG, Ehrentraut S, Geffers R, MacLeod RA, Nagel S, Pommerenke C, Romani J, Scherr M, Vaas LA, Zaborski M, Drexler HG, Quentmeier H.

Haematologica. 2015 Jun;100(6):801-9. doi: 10.3324/haematol.2014.120048. Epub 2015 Mar 13.

19.

[Expression of microRNA-223 in lymphocytic leukemia cells and its action mechanism].

Nan Z, Liang Y, Fu R, Liu H, Ruan EB, Wang XM, Wang GJ, Qu W, Liu H, Wu YH, Song J, Xing LM, Guan J, Li LJ, Wang HQ, Shao ZH.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Jun;21(3):556-61. doi: 10.7534/j.issn.1009-2137.2013.03.004. Chinese.

PMID:
23815897
20.

LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.

Malumbres R, Fresquet V, Roman-Gomez J, Bobadilla M, Robles EF, Altobelli GG, Calasanz MJ, Smeland EB, Aznar MA, Agirre X, Martin-Palanco V, Prosper F, Lossos IS, Martinez-Climent JA.

Haematologica. 2011 Jul;96(7):980-6. doi: 10.3324/haematol.2011.040568. Epub 2011 Apr 1.

Items per page

Supplemental Content

Write to the Help Desk